Use of n-methyltyramine for the preparation of a medicament for improving angry and irritable mood

By directly targeting the GABAa receptor with N-methyltyramine and positively regulating its downstream signaling pathways, the problem of slow onset and significant side effects of existing drugs has been solved, achieving effective improvement of anger and irritability, and providing a novel drug for mood disorders.

CN122320931APending Publication Date: 2026-07-03SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
Filing Date
2026-05-20
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Existing medications for improving anger and irritability have problems such as slow onset of action, insufficient targeting, significant side effects, and the potential for dependence with long-term use.

Method used

Using N-methyltyramine (NMT) as a positive regulator that directly targets GABAa receptors, it positively modulates the AC5-cAMP-PKA signaling pathway downstream of GABAa receptors by enhancing the inhibitory neurotransmission function mediated by GABAaR, thereby improving anger and irritability.

Benefits of technology

NMT significantly enhances AC5 protein expression in the hippocampus, restores impaired second messenger transmission function under abnormal emotional states, and activates the GABAaR-related signaling axis, providing an effective means of prevention and treatment for mood disorders, with good safety and application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122320931A_ABST
    Figure CN122320931A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of N-methyltyramine in the preparation of drugs for improving anger and irritability. The CAS number of the N-methyltyramine (NMT) is 370-98-9. Experimental results show that NMT can directly target and positively regulate the γ-aminobutyric acid type A receptor (GABA). a NMT activates the downstream AC5-cAMP-PKA signaling pathway, thereby improving abnormal emotional states such as anger and depression. Through network pharmacology, molecular docking, micro-thermophoresis experiments, animal behavioral experiments, and cell experiments, NMT significantly improves the behavior of model animals. Therefore, this invention reveals for the first time that NMT improves abnormal emotional states such as anger and depression through GABA. a The mechanism by which R-related signaling pathways play a role in mood regulation can be used to prepare drugs for treating mood disorders such as anxiety, depression, and post-traumatic stress disorder, and has good application prospects.
Need to check novelty before this filing date? Find Prior Art